MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) today provided an increased guidance for the financial year 2006. On the basis of new collaborations and the expansion of the collaboration with Novartis, an outperformance of revenues versus guidance was identified for the current year in the amount of up to EUR 2 million, which could increase 2006 revenues from EUR 50 million to up to EUR 52 million. Scope for reduction on expense guidance for the full year was also given, with a decrease in expenses of up to EUR 3 million, which could decrease expenses for the full year 2006 from EUR 49 million to EUR 46 million. The impact of these changes could result in earnings before interest and taxes (EBIT) of up to EUR 6 million. Future Company financial guidance will be provided on an EBIT basis only. For comparative purposes, non-operating expenses are estimated at approx. EUR 1 million, resulting in a potential net profit of up to EUR 5 million (original guidance: EUR 1 million).